Free Trial

Niagen Bioscience (NAGE) Competitors

Niagen Bioscience logo
$11.84 +0.06 (+0.51%)
As of 01:52 PM Eastern

NAGE vs. ACLX, ALVO, ZLAB, RARE, VKTX, CPRX, MTSR, MOR, PTGX, and CRNX

Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Arcellx (ACLX), Alvotech (ALVO), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Metsera (MTSR), MorphoSys (MOR), Protagonist Therapeutics (PTGX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

Niagen Bioscience vs.

Arcellx (NASDAQ:ACLX) and Niagen Bioscience (NASDAQ:NAGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.

Arcellx has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.

Arcellx received 68 more outperform votes than Niagen Bioscience when rated by MarketBeat users. However, 100.00% of users gave Niagen Bioscience an outperform vote while only 83.13% of users gave Arcellx an outperform vote.

CompanyUnderperformOutperform
ArcellxOutperform Votes
69
83.13%
Underperform Votes
14
16.87%
Niagen BioscienceOutperform Votes
1
100.00%
Underperform Votes
No Votes

In the previous week, Niagen Bioscience had 2 more articles in the media than Arcellx. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Arcellx. Arcellx's average media sentiment score of 1.75 beat Niagen Bioscience's score of 0.57 indicating that Arcellx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcellx
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Niagen Bioscience
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Niagen Bioscience has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Niagen Bioscience's return on equity of 0.00% beat Arcellx's return on equity.

Company Net Margins Return on Equity Return on Assets
Arcellx-25.94% -8.28% -5.21%
Niagen Bioscience N/A N/A N/A

96.0% of Arcellx shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 8.4% of Arcellx shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arcellx currently has a consensus price target of $111.33, suggesting a potential upside of 66.57%. Niagen Bioscience has a consensus price target of $13.00, suggesting a potential upside of 10.26%. Given Arcellx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcellx is more favorable than Niagen Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcellx
0 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
3.07
Niagen Bioscience
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Niagen Bioscience has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcellx$76.81M47.95-$70.69M-$2.99-22.35
Niagen Bioscience$107.93M8.61$13.39M$0.1769.35

Summary

Niagen Bioscience beats Arcellx on 11 of the 19 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAGE vs. The Competition

MetricNiagen BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ Exchange
Market Cap$928.70M$464.92M$2.03B$8.56B
Dividend YieldN/AN/A2.63%4.20%
P/E Ratio69.3523.1422.6619.93
Price / Sales8.614.3162.70147.95
Price / CashN/AN/A51.7234.64
Price / BookN/AN/A2.124.62
Net Income$13.39MN/A-$292.00M$248.05M
7 Day Performance7.38%16.23%1.66%2.16%
1 Month PerformanceN/AN/A7.72%7.75%
1 Year PerformanceN/AN/A15.09%11.36%

Niagen Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAGE
Niagen Bioscience
0.3889 of 5 stars
$11.84
+0.5%
$13.00
+9.8%
N/A$932.64M$107.93M69.65120News Coverage
ACLX
Arcellx
2.3189 of 5 stars
$61.70
-0.4%
$111.33
+80.4%
+21.4%$3.40B$76.81M-86.9080Positive News
ALVO
Alvotech
2.4728 of 5 stars
$11.28
-0.5%
$18.00
+59.6%
-18.0%$3.40B$585.60M-6.094Short Interest ↓
ZLAB
Zai Lab
2.7845 of 5 stars
$30.44
-1.9%
$47.37
+55.6%
+72.9%$3.36B$418.33M-11.001,950Positive News
Short Interest ↓
Gap Up
RARE
Ultragenyx Pharmaceutical
3.9241 of 5 stars
$34.24
-2.4%
$89.31
+160.8%
-11.5%$3.24B$590.69M-5.401,310Positive News
VKTX
Viking Therapeutics
4.5533 of 5 stars
$27.41
+0.8%
$87.15
+218.0%
-57.3%$3.08BN/A-27.3920Positive News
CPRX
Catalyst Pharmaceuticals
4.8856 of 5 stars
$24.59
-1.0%
$32.29
+31.3%
+54.0%$3.00B$534.65M20.8380Positive News
Analyst Revision
MTSR
Metsera
N/A$28.14
+1.1%
$47.00
+67.0%
N/A$2.96BN/A0.0081
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
PTGX
Protagonist Therapeutics
3.2697 of 5 stars
$46.00
-0.9%
$65.44
+42.3%
+71.3%$2.85B$207.80M17.29120Positive News
Analyst Forecast
Short Interest ↓
CRNX
Crinetics Pharmaceuticals
3.7343 of 5 stars
$30.18
+2.3%
$74.56
+147.1%
-30.6%$2.82B$760,000.00-8.08210Positive News

Related Companies and Tools


This page (NASDAQ:NAGE) was last updated on 6/4/2025 by MarketBeat.com Staff
From Our Partners